Sinusitis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Sinusitis – Pipeline Review, H2 2019’, provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Sinusitis

– The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects

– The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Sinusitis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sinusitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AnaptysBio Inc

Argenx SE

Armata Pharmaceuticals Inc

Beijing Fogangren Bio-Pharm Tech Co Ltd

Furen Pharmaceutical Group Co Ltd.

GeneOne Life Science Inc

GlycoMira Therapeutics Inc

Gossamer Bio Inc

Intrexon Corp

IVIEW Therapeutics Inc

Knopp Biosciences LLC

Kyowa Kirin Co Ltd

Lyra Therapeutics

Merck & Co Inc

Nota Laboratories LLC

OptiNose US Inc

Pfizer Inc

ProclaRx LLC

Quorum Innovations LLC

RAPT Therapeutics Inc

Sanotize Research And Development Corp

Therabron Therapeutics Inc

Wuhan Yicheng Biotechnology Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sinusitis Overview

Sinusitis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Sinusitis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sinusitis Companies Involved in Therapeutics Development

AmpliPhi Biosciences Corp

AnaptysBio Inc

F. Hoffmann-La Roche Ltd

Intrexon Corp

Knopp Biosciences LLC

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Lyra Therapeutics

Merck & Co Inc

OptiNose US Inc

Pfizer Inc

Quorum Innovations LLC

Therabron Therapeutics Inc

Sinusitis Drug Profiles

ABSA-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-018 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexpramipexole dihydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etokimab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lascufloxacin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mometasone furoate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NORS-1002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1550 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06817024 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Rhino sinusitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sinusitis Dormant Projects

Sinusitis Discontinued Products

Sinusitis Product Development Milestones

Featured News & Press Releases

Sep 17, 2018: Lyra Therapeutics to Present Clinical Data from Phase 1 Study of LYR-210 for the Treatment of Chronic Rhino sinusitis

May 21, 2018: Summit Medical Group Research Aids in FDA Approval of Drug for Nasal Polyps

Feb 27, 2018: Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress

Oct 30, 2017: Optinose Expands Leadership Team with Key Hires

Apr 17, 2017: AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal

Apr 04, 2017: AmpliPhi Biosciences Presents Clinical and Preclinical Data of Pipeline Program AB-SA01 at Two Scientific Conferences

Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials

Jan 04, 2017: Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhino sinusitis Patients

Dec 19, 2016: AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhino sinusitis Patients

Oct 25, 2016: AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhino sinusitis

Sep 20, 2016: AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhino sinusitis Patients

Sep 16, 2016: OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhino sinusitis with and without Nasal Polyps

Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress

Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus

Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Sinusitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Sinusitis – Pipeline by AnaptysBio Inc, H2 2019

Sinusitis – Pipeline by Argenx SE, H2 2019

Sinusitis – Pipeline by Armata Pharmaceuticals Inc, H2 2019

Sinusitis – Pipeline by Beijing Fogangren Bio-Pharm Tech Co Ltd, H2 2019

Sinusitis – Pipeline by Furen Pharmaceutical Group Co Ltd., H2 2019

Sinusitis – Pipeline by GeneOne Life Science Inc, H2 2019

Sinusitis – Pipeline by GlycoMira Therapeutics Inc, H2 2019

Sinusitis – Pipeline by Gossamer Bio Inc, H2 2019

Sinusitis – Pipeline by Intrexon Corp, H2 2019

Sinusitis – Pipeline by IVIEW Therapeutics Inc, H2 2019

Sinusitis – Pipeline by Knopp Biosciences LLC, H2 2019

Sinusitis – Pipeline by Kyowa Kirin Co Ltd, H2 2019

Sinusitis – Pipeline by Lyra Therapeutics, H2 2019

Sinusitis – Pipeline by Merck & Co Inc, H2 2019

Sinusitis – Pipeline by Nota Laboratories LLC, H2 2019

Sinusitis – Pipeline by OptiNose US Inc, H2 2019

Sinusitis – Pipeline by Pfizer Inc, H2 2019

Sinusitis – Pipeline by ProclaRx LLC, H2 2019

Sinusitis – Pipeline by Quorum Innovations LLC, H2 2019

Sinusitis – Pipeline by RAPT Therapeutics Inc, H2 2019

Sinusitis – Pipeline by Sanotize Research And Development Corp, H2 2019

Sinusitis – Pipeline by Therabron Therapeutics Inc, H2 2019

Sinusitis – Pipeline by Wuhan Yicheng Biotechnology Co Ltd, H2 2019

Sinusitis – Dormant Projects, H2 2019

Sinusitis – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Sinusitis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports